You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Germ Cell Tumor

Showing 9976 - 10000 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Referral Patterns for High Risk Patients Post Nephrectomy

Completed
Has Results
  • Renal Cell Carcinoma
  • nephrectomy
  • Durham, North Carolina
    Duke University
Apr 27, 2021

Sickle Cell Disease, Pain Trial in Bronx (Immune Globulin Intravenous, Normal saline)

Recruiting
  • Sickle Cell Disease
  • Pain
  • Immune Globulin Intravenous
  • Normal saline
  • Bronx, New York
    Montefiore Medical Center
Jul 25, 2022

Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination

Not yet recruiting
  • Salivary Gland Cancer
  • vedicitumomab (Edisil, RC48）
  • +3 more
  • (no location specified)
Jun 9, 2023

Tumors Trial in Miami, Tampa, Houston (letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine)

Completed
Has Results
  • Neoplasms
  • letetresgene autoleucel (GSK3377794)
  • +2 more
  • Miami, Florida
  • +2 more
Aug 10, 2021

Multidimensional Aspects of QUAlity of Life After Cancer

Recruiting
  • Solid Tumor
  • Hematologic Cancer
  • QoL & irAEs determinants
  • Pierre-Bénite, France
  • +4 more
Nov 15, 2022

Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease Trial in Little Rock, Bronx,

Enrolling by invitation
  • Sickle Cell Disease
  • +2 more
  • Little Rock, Arkansas
  • +2 more
Jun 30, 2022

Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

Recruiting
  • Leukemia, Acute Lymphocytic
  • Durham, North Carolina
    Duke Cancer Center
Jun 28, 2022

Advanced Solid Tumor Trial in New York, Houston, Salt Lake City (RP-6306 (oral PKMYT1 inhibitor))

Recruiting
  • Advanced Solid Tumor
  • RP-6306 (oral PKMYT1 inhibitor)
  • New York, New York
  • +2 more
Jun 21, 2022

Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • B-Cell Lymphoproliferative Disorder
  • Boston, Massachusetts
  • +2 more
Feb 18, 2023

Cost-effectiveness Analysis of Cadonilimab in Treatment of

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Nov 18, 2023

Glioblastoma Trial in Rochester (radiation, procedure, drug, other)

Recruiting
  • Glioblastoma
  • Accelerated Hypofractionated Radiation Therapy
  • +8 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Mar 24, 2023

NSCLC Trial in Villejuif (PET-MRI)

Unknown status
  • NSCLC
  • PET-MRI
  • Villejuif, Val De Marne, France
    Gustave Roussy
Jan 2, 2019

NSCLC Trial in Oslo (UV1 synthetic peptide vaccine and GM-CSF)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • UV1 synthetic peptide vaccine and GM-CSF
  • Oslo, Norway
    Oslo University Hospital
May 14, 2021

Vascular Thrombus Involvement in Nephroblastoma

Not yet recruiting
  • Nephroblastoma With Vena Cava Thrombosis
    • Le Kremlin Bicêtre, France
    • +1 more
    Jan 4, 2022

    Measures After Treatment of Skin Cancers on the Face

    Recruiting
    • Skin Cancer
    • data collection by questionnaires
    • data collection (photos of the patients' tumors)
    • Basel, Switzerland
      Department of Plastic, Reconstructive and Aesthetic Surgery and
    Mar 1, 2022

    Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in

    Active, not recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia
    • +125 more
    • tetanus-CMV fusion peptide vaccine
    • laboratory biomarker analysis
    • Duarte, California
      City of Hope Medical Center
    Feb 28, 2022

    Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors Trial in Beijing (Chidamide, Decitabine, Immune checkpoint

    Recruiting
    • Relapsed/Refractory Non-Hodgkin Lymphoma
    • Advanced Solid Tumors
    • Beijing, Beijing, China
      Biotherapeutic Department, Chinese PLA General Hospital
    Apr 8, 2022

    Non Small Cell Lung Cancer Trial in Worldwide (HM61713)

    Terminated
    • Non Small Cell Lung Cancer
    • Beverly Hills, California
    • +71 more
    Jan 17, 2021

    Biliary Tract Tumors, Liver Cancer, Hepatocellular Carcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Trans-arterial

    Active, not recruiting
    Has Results
    • Biliary Tract Neoplasms
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Mar 1, 2022

    Early Outcome After Islet Transplantation

    Not yet recruiting
    • Islets of Langerhans Transplantation
    • +2 more
      • Leiden, Zuid-Holland, Netherlands
        Leiden University Medical Center
      Sep 9, 2022

      Dengue Trial in Lausanne (LD vehicle-GNP, LD PepGNP-Dengue, HD vehicle-GNP)

      Completed
      • Dengue
      • LD vehicle-GNP
      • +3 more
      • Lausanne, Vaud, Switzerland
        Center for Primary Care and Public Health, (Unisante)
      Nov 28, 2022

      CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

      Active, not recruiting
      • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
      • DISEASE
      • (no location specified)
      May 4, 2023

      NSCLC, NSCLC Stage III, Recurrent Non Small Cell Lung Cancer Trial (Garmin Vivofit Activity Tracker)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • +2 more
      • Garmin Vivofit Activity Tracker
      • (no location specified)
      Aug 31, 2022

      Chronic Inflammation, Overweight Trial in Kannapolis (Placebo, Palmitoleic acid, 500 mg (Dose 1), Palmitoleic acid, 1,000 mg

      Recruiting
      • Chronic Inflammation
      • Overweight
      • Placebo
      • +2 more
      • Kannapolis, North Carolina
        University of North Carolina Nutrition Research Institute
      Sep 29, 2021

      Acute Myeloid Leukemia Trial in Wuxi (Anti-CD33/CLL1 CAR-NK Cells)

      Recruiting
      • Acute Myeloid Leukemia
      • Anti-CD33/CLL1 CAR-NK Cells
      • Wuxi, Jiangsu, China
        Wuxi People's Hospital
      Jan 18, 2022